Alis Biosciences then plans to list and offer big investors an easy way to spread their bets
Deal is latest sign of the uptick in exits by private equity groups despite sluggish M&A activity
Acquisitions hold cure for pharma companies’ chronic patent cliff problem
Once researchers begin wondering whether their government might pull the rug from under them, the damage is done
The biotech group created a revolutionary technology but it never hit on a sustainable business
DNA sequencing specialist’s decision to list in London in 2021 was seen as a victory for the market at the time
The city’s ecosystem of universities, commerce and research is attracting investors and start-ups
BioArctic is developing a process to allow drugs to cross the layer of cells that protects the brain
Simon Kohl aims to capitalise on his experience with Nobel-recognised AlphaFold protein prediction system
Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019
Western drugmakers look to Chinese trials for early data on treatments’ potential success
Albert Bourla says Donald Trump’s nominee for health secretary still appeared to ‘temper’ some of his views
The San Francisco-based start-up plans to get its first drug into trials this year
A flurry of pharma deals on the first day of a major industry gathering could herald a pick-up in M&A
Early Tesla backer is developing financing plan to allow fresh shot at FDA approval for ecstasy-based PTSD treatment
Verdiva Bio wants to use potential drugs acquired in China to compete in growing obesity market
IDRx tests treatment for digestive system cancer that affects 4,000 to 6,000 people a year in US
Autolus hopes its less gruelling Car-T treatment for a type of leukaemia will allow it to compete with bigger rivals
Appetite will pick up as interest rates fall, but uneven distribution of funding and rewards looks set to persist
Boss David Epstein hopes to replicate his success at Seagen after $43bn sale last year
Experts forecast Trump administration could usher in new era of mergers and acquisitions among drugmakers
Abingworth wants to pursue royalty-based partnerships with major pharma groups
Trump nominee's vaccine scepticism worries industry
Trump nominee has caused concern in the industry due to his desire to reduce spending on medicines
Former investors and board members reduce holdings in the once much-hyped genetics-testing group
